Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Larimar Therapeutics (LRMR) Income from Continuing Operations (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Income from Continuing Operations for 7 consecutive years, with 6185000.0 as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Income from Continuing Operations rose 57.39% year-over-year to 6185000.0, compared with a TTM value of 27269000.0 through Dec 2019, up 55.39%, and an annual FY2024 reading of 90890000.0, down 117.66% over the prior year.
  • Income from Continuing Operations was 6185000.0 for Q4 2019 at Larimar Therapeutics, up from 12881000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 4932000.0 in Q2 2019 and bottomed at 23233000.0 in Q4 2015.
  • Average Income from Continuing Operations over 5 years is 13630450.0, with a median of 13964500.0 recorded in 2015.
  • The sharpest move saw Income from Continuing Operations crashed 196.57% in 2015, then surged 131.41% in 2019.
  • Year by year, Income from Continuing Operations stood at 23233000.0 in 2015, then surged by 55.49% to 10342000.0 in 2016, then fell by 26.76% to 13110000.0 in 2017, then dropped by 10.72% to 14515000.0 in 2018, then skyrocketed by 57.39% to 6185000.0 in 2019.
  • Business Quant data shows Income from Continuing Operations for LRMR at 6185000.0 in Q4 2019, 12881000.0 in Q3 2019, and 4932000.0 in Q2 2019.